Septerna, Inc. (SEPN)
NASDAQ:SEPN
Want to see SEPN full AI Analyst Report?
Top Page
Septerna, Inc.
(NASDAQ:SEPN)
Select Model
Select Model
Rating:57Neutral
Price Target:
$26.00
▼(-0.50% Downside)
Action:Reiterated
Date:05/14/26
The score is driven primarily by improved fundamentals—especially the shift to strong positive operating and free cash flow and a conservatively levered balance sheet—offset by continued large operating losses. Technical signals are neutral-to-slightly weak, valuation is constrained by negative earnings and no dividend support, while recent positive clinical-stage updates provide a meaningful (but early-stage) catalyst.
Positive Factors
Pipeline clinical progress
Positive Phase 1 proof-of-mechanism for SEP-631 and plans for a randomized global Phase 2b create durable program de-risking. Clinical validation supports platform credibility, broadens indication potential, and strengthens future licensing or commercialization opportunities over the next 2–6 months and beyond.
Negative Factors
Persistent operating losses
Despite revenue acceleration, entrenched negative operating and net margins indicate the business still does not cover operating expenses. Over months, sustained losses constrain reinvestment capacity, increase funding needs for commercialization, and keep profitability timelines uncertain.
Read all positive and negative factors
Positive Factors
Negative Factors
Pipeline clinical progress
Positive Phase 1 proof-of-mechanism for SEP-631 and plans for a randomized global Phase 2b create durable program de-risking. Clinical validation supports platform credibility, broadens indication potential, and strengthens future licensing or commercialization opportunities over the next 2–6 months and beyond.
Read all positive factors
Septerna, Inc. (SEPN) vs. SPDR S&P 500 ETF (SPY)
Market Cap
$1.28B
Dividend YieldN/A
Average Volume (3M)351.66K
Price to Earnings (P/E)―
Beta (1Y)2.14
Revenue Growth7295.60%
EPS Growth58.57%
CountryUS
Employees75
SectorTechnology
Sector Strength88
IndustryBiotechnology
Share Statistics
EPS (TTM)-0.81
Shares Outstanding45,075,535
10 Day Avg. Volume347,669
30 Day Avg. Volume351,661
Financial Highlights & Ratios
PEG Ratio0.59
Price to Book (P/B)3.23
Price to Sales (P/S)26.85
P/FCF Ratio11.25
Enterprise Value/Market Cap0.96
Enterprise Value/Revenue17.02
Enterprise Value/Gross Profit17.12
Enterprise Value/Ebitda-18.48
Forecast
1Y Price Target
$42.25Price Target Upside61.69% Upside
Rating ConsensusStrong Buy
Number of Analyst Covering6
EPS Forecast (FY)-1.71
Revenue Forecast (FY)$74.06M
Septerna, Inc. Business Overview & Revenue Model
Company Description
Septerna, Inc., a clinical-stage biotechnology company, discovers and develops G protein-coupled receptor (GPCR) oral small molecule products candidates for the treatment of endocrinology, immunology and inflammation, and metabolic diseases. The c...
How the Company Makes Money
null...
Septerna, Inc. Financial Statement Overview
Summary
Income Statement
38
Negative
Balance Sheet
72
Positive
Cash Flow
67
Positive
| Breakdown | TTM | Dec 2025 | Dec 2024 | Dec 2023 | Dec 2022 |
|---|---|---|---|---|---|
Income Statement | |||||
| Total Revenue | 72.25M | 45.95M | 1.07M | 151.00K | 0.00 |
| Gross Profit | 71.83M | 45.95M | 1.07M | 151.00K | 0.00 |
| EBITDA | -66.56M | -79.19M | -79.42M | -44.70M | -27.39M |
| Net Income | -36.04M | -48.88M | -71.80M | 4.18M | -27.68M |
Balance Sheet | |||||
| Total Assets | 569.69M | 596.19M | 456.55M | 130.87M | 36.12M |
| Cash, Cash Equivalents and Short-Term Investments | 347.40M | 391.09M | 350.92M | 88.48M | 30.61M |
| Total Debt | 23.09M | 23.63M | 25.48M | 12.57M | 710.00K |
| Total Liabilities | 191.23M | 214.26M | 36.51M | 169.24M | 80.32M |
| Stockholders Equity | 378.46M | 381.93M | 420.05M | -38.37M | -44.20M |
Cash Flow | |||||
| Free Cash Flow | 106.93M | 109.67M | -69.57M | -41.60M | -24.59M |
| Operating Cash Flow | 107.90M | 110.19M | -67.47M | -38.72M | -23.30M |
| Investing Cash Flow | -248.29M | -229.35M | -160.60M | 22.12M | -1.29M |
| Financing Cash Flow | 1.96M | 1.69M | 377.78M | 74.52M | 30.05M |
Septerna, Inc. Technical Analysis
Positive
26.13
Price Trends
24.94
Positive
25.91
Positive
22.94
Positive
Market Momentum
0.78
Negative
62.71
Neutral
81.40
Negative
Evaluating momentum and price trends is crucial in stock analysis to make informed investment decisions. For SEPN, the sentiment is Positive. The current price of 26.13 is above the 20-day moving average (MA) of 25.36, above the 50-day MA of 24.94, and above the 200-day MA of 22.94, indicating a bullish trend. The MACD of 0.78 indicates Negative momentum. The RSI at 62.71 is Neutral, neither overbought nor oversold. The STOCH value of 81.40 is Negative, not indicating any strong overbought or oversold conditions. Overall, these indicators collectively point to a Positive sentiment for SEPN.
Septerna, Inc. Risk Analysis
Septerna, Inc. disclosed 89 risk factors in its most recent earnings report. Septerna, Inc. reported the most risks in the "Tech & Innovation" category.
Finance & Corporate - Financial and accounting risks. Risks related to the execution of corporate activity and strategy
Latest Risks Added 0 New Risks
Septerna, Inc. Peers Comparison
UnderperformOutperform
Sector (61)
Name | Overall Rating | Market Cap | P/E Ratio | ROE | Dividend Yield | Revenue Growth | EPS Growth |
|---|---|---|---|---|---|---|---|
70 Outperform | $843.92M | -42.18 | 43.85% | ― | 68.20% | ― | |
61 Neutral | $37.18B | 12.37 | -10.20% | 1.83% | 8.50% | -7.62% | |
61 Neutral | $998.71M | -2.46 | -141.95% | ― | 5.37% | -60.20% | |
57 Neutral | $1.28B | -31.13 | -9.44% | ― | 7295.60% | 58.57% | |
55 Neutral | $1.14B | -27.75 | -44.72% | ― | -15.35% | 37.09% | |
43 Neutral | $49.31M | -0.41 | 174.85% | ― | -55.42% | -248.85% |
* Technology Sector Average
SEPN
Septerna, Inc.
28.36
18.71
193.89%
TBPH
Theravance Biopharma
16.37
7.07
76.02%
KURA
Kura Oncology
11.25
5.61
99.47%
GOSS
Gossamer Bio
0.21
-0.99
-82.50%
MRVI
Maravai Lifesciences Holdings
4.40
2.18
98.20%
Septerna, Inc. Corporate Events
Business Operations and StrategyProduct-Related Announcements
Septerna Begins Phase 1 Trial of Oral SEP-479
Positive
Apr 13, 2026
On April 13, 2026, Septerna, Inc. reported that it has begun dosing participants in a Phase 1 clinical trial of SEP-479, an oral small molecule parathyroid hormone 1 receptor agonist being developed to treat hypoparathyroidism. The program targets...
Business Operations and StrategyProduct-Related Announcements
Septerna Advances SEP-631 After Positive Phase 1 Results
Positive
Mar 2, 2026
On March 1, 2026, Septerna reported positive Phase 1 results for SEP-631, an oral negative allosteric modulator of MRGPRX2 being developed for chronic spontaneous urticaria and other mast cell-driven diseases. In healthy volunteers, SEP-631 was we...
Glossary
BuyA stock rated as a "Buy" is expected to perform better than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock is likely to deliver higher returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
HoldA stock rated as a "Hold" is expected to perform in line with the overall market or a specific benchmark. This rating indicates that the stock is neither particularly compelling nor unfavorable for investment. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
SellA stock rated as a "Sell" is expected to perform worse than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock may deliver lower returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
Disclaimer
This AI Analyst Stock Report is automatically generated by our AI systems using advanced algorithms and publicly available financial, technical, and market data. While the information provided aims to be accurate and insightful, it is intended for informational purposes only and should not be considered financial advice. Any content created by an AI (Artificial Intelligence) system may contain inaccuracies and/or contain errors. Investing in stocks carries inherent risks, and past performance is not indicative of future results. This report does not account for your personal financial circumstances, objectives, or risk tolerance. Always conduct your own research or consult with a qualified financial advisor before making investment decisions. The analysis and recommendations provided are based on historical and current data and may not fully reflect future market conditions or unexpected developments. Neither the creators of this report nor its affiliated entities guarantee the accuracy, completeness, or reliability of the information presented. Use this report at your own discretion and risk.